Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

BPC Dosage: How Research Uses This Peptide (No Medical Advice)

Back to library
peptide

BPC Dosage: How Research Uses This Peptide (No Medical Advice)

14 min read
Preclinical Research
BPC-157
Peptide Science
Tissue Research
Last Updated: May 2026

BPC-157 (Body Protective Compound-157) is one of the most extensively searched peptides in the research community — and “BPC dosage” is among the first questions researchers ask when they begin investigating it. The honest answer, and the one this article gives you, is that BPC-157 does not have a completed human clinical trial to draw from. There is no established human dose. What does exist is a growing body of preclinical research — animal models, in vitro cell studies, and mechanistic investigations — that have used specific quantities in those experimental contexts. This article explains exactly what those studies used, why no prescriptive BPC-157 dosage guidance exists, and what that means for research design.

BPC-157 10mg is available from Pure Grade Labs as a research-grade chemical, supplied strictly for laboratory research purposes. Not for human consumption. If you arrived here looking for prescriptive dosing guidance, that falls outside what this article — or any responsible source — can provide without completed Phase I/II human trial data.

Key Takeaways

  • BPC-157 is a 15-amino acid synthetic peptide (CAS: 137525-51-0) derived from a protective protein in human gastric juice — not a pharmaceutical with approved human dosing.
  • No completed Phase I or Phase II human clinical trials for BPC-157 have been published at the time of writing — this is the single most important fact distinguishing BPC dosage questions from, say, semaglutide dosage questions.
  • Published preclinical rodent studies have used doses in the range of 2–10 µg/kg administered via intraperitoneal injection — but these are experimental parameters in animal models, not human dosing recommendations.
  • In vitro research has demonstrated cytoprotective effects of BPC-157 at nanomolar concentrations in cell culture models, consistent with its high biological potency per unit mass.
  • Researchers sourcing BPC-157 for preclinical work can also access related compounds including TB-500 and the Injury Recovery Research Stack from Pure Grade Labs.
15
Amino acids in BPC-157 — one of the smallest synthetic peptides with a documented multi-system preclinical research profile
10 µg/kg
Dose used per kg body weight in Sikiric et al. rodent model studies — an experimental parameter in animal research, not a human recommendation
0
Completed Phase I or Phase II human clinical trials for BPC-157 published as of May 2026 — distinguishing it from approved pharmaceuticals
nM
Nanomolar concentrations at which BPC-157 has shown cytoprotective effects in in vitro cell culture studies, indicating high potency per unit mass

BPC-157 — Research Grade Supply

HPLC-verified purity, batch-specific Certificate of Analysis. BPC-157 10mg available now. For laboratory research only. Not for human consumption.

View BPC-157 10mg →

What Is BPC-157?

BPC-157 — Body Protective Compound-157 — is a synthetic 15-amino acid peptide fragment derived from a protective protein naturally found in human gastric juice. Its full amino acid sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It was identified and characterised primarily through the work of Professor Predrag Sikiric and colleagues at the University of Zagreb, whose research group has produced much of the published preclinical literature on the compound.

BPC157 (also written BPC-157 with a hyphen) has a molecular weight of 1,419.53 Da and the CAS registry number 137525-51-0. It is not naturally found in appreciable concentrations in circulation; rather, the gastric-origin protein from which it is derived is present in the gut lining as part of its cytoprotective architecture. The synthetic fragment was developed for research use to study the mechanisms of that cytoprotection in controlled experimental settings.

BPC-157 Molecular Profile

Parameter Value
Full name Body Protective Compound-157
CAS number 137525-51-0
Amino acid count 15
Molecular weight 1,419.53 Da
Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Origin Synthetic fragment derived from human gastric protective protein
Human clinical trial status No completed Phase I or Phase II trials published (as of May 2026)

BPC-157 Mechanism of Action: What Research Has Studied

The mechanisms attributed to BPC-157 in preclinical literature are multi-pathway, which is one reason it has attracted research interest across diverse tissue systems. Published studies have focused on several distinct biological pathways:

Nitric Oxide (NO) Pathway Modulation

A significant body of research from the Sikiric group (University of Zagreb) has implicated BPC-157 in the upregulation of nitric oxide synthase (NOS) activity and downstream NO signalling. Nitric oxide is central to vascular tone, endothelial integrity, and local tissue perfusion — making this mechanism of particular interest in tissue repair research contexts where vascularisation is a rate-limiting factor.

Angiogenesis Promotion

Multiple preclinical studies have demonstrated BPC-157’s capacity to promote angiogenesis — the formation of new blood vessels from existing vasculature. Chang CH et al. (2011, Journal of Applied Physiology) demonstrated enhanced tendon-to-bone healing in rat models, with vascular ingrowth as one of the proposed mediating mechanisms. This angiogenic activity is also consistent with the in vitro findings of cytoprotective effects at nanomolar concentrations in cultured endothelial cell models.

Growth Factor Upregulation

Published literature has reported BPC-157 administration in animal models to be associated with upregulation of growth factor expression, including VEGF (vascular endothelial growth factor) and EGF receptor pathways. These findings are consistent with the observed downstream effects in tissue repair models, though causality and exact molecular binding targets require further elucidation.

Gastrointestinal Cytoprotection

The compound’s origin from gastric protective protein is reflected in its robust preclinical data in GI research contexts. Studies have investigated BPC-157 in models of gastric ulceration, intestinal anastomosis, inflammatory bowel disease analogue models, and NSAID-induced gut damage — areas where the Sikiric group has published extensively over the past two decades.

When a research team designing a tendon healing study asks about BPC dosage, the first step in answering them correctly is clarifying the unit of measurement used in the source literature: rodent studies express doses in micrograms per kilogram of body weight (µg/kg), administered intraperitoneally. Sikiric et al. (2018) used 10 µg/kg as the primary experimental dose in multiple rodent repair models — with 2 µg/kg also tested to explore dose-dependency. Understanding that these are parameters calibrated for Sprague-Dawley rat physiology, not human dosing equivalents, is the foundational literacy required before any research protocol can be designed responsibly. This distinction matters because BPC-157 has never been through the dose-escalation Phase I human trials that establish safe starting doses in people.

What Doses Did Published BPC-157 Research Use?

This is the core of the “BPC dosage” question as it appears in the research literature. The published studies that have explored BPC-157 effects in animal models have used the following experimental quantities. These are presented as research reference data only — they are not human dosing recommendations.

Study / Context Model Dose Used Route
Sikiric et al. (2018) Rodent tissue repair models 10 µg/kg (primary); 2 µg/kg (secondary) Intraperitoneal (IP)
Chang CH et al. (2011, J Appl Physiol) Rat tendon-to-bone healing 10 µg/kg IP injection
DeFoor MT et al. (2024, Arthroscopy, PMC12313605) Orthopaedic preclinical review Range reviewed: 1–10 µg/kg Various (IP, oral, local)
In vitro cell culture studies Cultured cell cytoprotection models Nanomolar (nM) range Media supplementation

The critical point in interpreting this data: there is no corresponding human trial dose to benchmark against. When a compound like semaglutide or tirzepatide is studied, decades of Phase I through Phase III human trial data exist — dose-response curves have been mapped in human subjects, NOAEL (no observed adverse effect level) values have been established, and prescribing guidance has been formally issued. BPC-157 has not been through this process. This is not an indictment of the compound’s research interest; it is simply the current state of the literature.

BPC-157 and TB-500 — Research Combination

Both compounds are frequently studied alongside each other in tissue repair research models. Available individually or together in the Wolverine Recovery Research Stack. For laboratory research only.

View Wolverine Research Stack →

Why There Is No Established Human BPC Dosage

Understanding why BPC-157 lacks an established human dosage requires understanding how the pharmaceutical development pipeline works. For a compound to have a validated human dose, it needs to have passed through the following stages:

Phase I Trials: First-in-Human Dose Escalation

Phase I trials take a compound with preclinical safety data and test it in humans for the first time — starting at a fraction of the animal model dose and escalating carefully to establish maximum tolerated dose, pharmacokinetics, and a preliminary safety profile. BPC-157 has not completed published Phase I trials. A Phase I registration (NCT identifier) has been listed, but no peer-reviewed results have been published at the time of writing.

Phase II Trials: Therapeutic Signal and Dose Optimisation

Phase II trials establish whether the compound produces a meaningful therapeutic signal in the target human population, and begin to refine the optimal dose range. Without Phase I data, Phase II cannot be responsibly initiated. BPC-157 is not at this stage in the formal regulatory pathway.

Contrast With Approved Compounds

Compare this to semaglutide, which has undergone multi-thousand-patient Phase III trials (SUSTAIN and STEP programmes), or tirzepatide (SURPASS programme). The prescribing doses for these compounds are grounded in rigorous human pharmacokinetic and pharmacodynamic data. BPC-157 simply does not have an equivalent evidence base at the human trial level. This places it firmly in the preclinical research category — which is where Pure Grade Labs positions and supplies it.

Research Applications: Where BPC-157 Is Being Studied

Despite the absence of human trial data, the preclinical literature on BPC-157 is extensive and spans multiple research domains. The following are the primary areas represented in published peer-reviewed studies:

Musculoskeletal and Connective Tissue Research

The DeFoor MT et al. (2024) review in Arthroscopy (PMC12313605) examined the body of published evidence on BPC-157 in orthopaedic research contexts — covering tendon, ligament, bone, and cartilage models. The review noted that while the preclinical data across these models is generally favourable in terms of observed tissue outcomes, the transition to human research had not yet occurred, making clinical translation speculative. This is precisely the gap that makes ongoing preclinical research valuable: establishing the mechanistic basis that would justify formal human investigation.

Gastrointestinal Research

BPC-157’s most extensive research literature is in the GI domain, which makes logical sense given its origin. Studies have examined effects in models of gastric ulceration, colitis, inflammatory bowel disease analogues, and gut barrier permeability. The Sikiric research group at the University of Zagreb has published over 100 papers examining BPC-157 in GI and related contexts — establishing it as one of the most studied experimental compounds in this space that has not yet entered clinical trials.

Neurological and Systemic Models

More recent published research has examined BPC-157 in neurological models, including CNS protection from various insults, dopaminergic system interactions (relevant to both neuroprotection and addiction models), and systemic inflammatory response attenuation in sepsis-like models. These represent expanding research frontiers that are at earlier preclinical stages than the musculoskeletal and GI literature.

Research Combination Interest: BPC-157 and TB-500

A notable area of research interest is the combination of BPC-157 with TB-500. These two compounds work through distinct, non-overlapping mechanisms — BPC-157 primarily through angiogenesis and growth factor upregulation, TB-500 through G-actin sequestration and cell migration. The mechanistic complementarity makes this research combination of particular interest in tissue repair models where multiple biological repair pathways are relevant simultaneously. Pure Grade Labs offers both compounds individually and as part of the Injury Recovery Research Stack and Wolverine Recovery Research Stack.

BPC-157 in Research: Reconstitution and Handling

BPC-157 is supplied as a lyophilised (freeze-dried) powder, which requires reconstitution before use in research protocols. The standard reconstitution vehicle in published studies is bacteriostatic water or sterile saline, depending on the experimental design and storage duration required. Pure Grade Labs supplies Bacteriostatic Water 10ml for this purpose — bacteriostatic water containing 0.9% benzyl alcohol to inhibit microbial growth, suitable for multi-draw vials where the solution will be stored after initial preparation.

In published animal model research, reconstituted BPC-157 has been administered via intraperitoneal injection (most commonly), oral gavage (for GI-focused studies), and in some studies via local administration directly to the tissue of interest. The choice of administration route is determined by the research question and the tissue system under investigation. These are experimental decisions made within the context of approved animal research protocols — they are not instructions for human use.

Frequently Asked Questions

What does “BPC dosage” mean in the context of research?

In a research context, “BPC dosage” refers to the quantity of BPC-157 used as an independent variable in preclinical experiments — expressed in µg/kg for in vivo animal studies, or in nanomolar/micromolar concentrations for in vitro cell culture work. These are experimental parameters calibrated to the model system used, not human dosing recommendations. The term is used frequently in search queries because researchers and students are trying to understand what published studies actually used in their protocols.

Has BPC-157 been through human clinical trials?

No completed Phase I or Phase II human clinical trials for BPC-157 have been published as of May 2026. A clinical trial registration exists but peer-reviewed results have not been published. This distinguishes BPC-157 from compounds like semaglutide or tirzepatide, which have extensive human pharmacokinetic and efficacy data. The absence of human trial data is the primary reason why no prescriptive BPC-157 dosage guidance can responsibly be offered.

What doses did Sikiric et al. use in their rodent research?

The Sikiric research group (University of Zagreb) used 10 µg/kg as the primary experimental dose in the majority of their rodent model studies, with 2 µg/kg also tested in some protocols to explore dose-dependency. These doses were administered via intraperitoneal injection in rodent subjects (typically Sprague-Dawley rats). These are experimental parameters for animal model research and cannot be extrapolated to human use without the intermediate step of formal Phase I human trials.

What is the legal status of BPC-157 in the UK?

BPC-157 is not a scheduled controlled substance under the Misuse of Drugs Act 1971, and it does not hold Prescription Only Medicine (POM) status in the UK, as it is not an approved pharmaceutical product. It can be legally supplied as a research chemical for laboratory use. Pure Grade Labs supplies BPC-157 10mg in this capacity — as a research chemical for laboratory research only, not for human consumption.

What reconstitution vehicle is used for BPC-157 in research?

Published animal studies typically use sterile saline (0.9% NaCl) or bacteriostatic water as the reconstitution vehicle for lyophilised BPC-157 powder. Bacteriostatic water is preferred when the reconstituted solution needs to be stored for multiple experimental sessions, as the benzyl alcohol preservative inhibits microbial growth. Pure Grade Labs supplies Bacteriostatic Water 10ml for research laboratory use.

How does BPC-157 compare to TB-500 as a research compound?

BPC-157 and TB-500 are complementary rather than interchangeable in research design. BPC-157 acts primarily through angiogenesis promotion and growth factor upregulation; TB-500 acts primarily through G-actin sequestration and cell migration pathway activation. These distinct, non-overlapping mechanisms explain why tissue repair research models have studied them as a research combination rather than substitutes for each other. The Injury Recovery Research Stack from Pure Grade Labs provides both compounds together.

Source BPC-157 With Verified Purity

Every batch HPLC-tested. Certificate of Analysis provided with each order. Lyophilised powder with QR-authenticated label. For laboratory research only. Not for human consumption.

Browse All Research Compounds →

Summary

The question of BPC dosage is a legitimate one for anyone engaging with the published literature on BPC-157. The honest and accurate answer is that BPC-157 (BPC157) lacks the completed human clinical trial data that would be required to establish a validated human dose. What exists are well-documented preclinical parameters from rodent model research — primarily from the Sikiric group at the University of Zagreb — using doses in the 2–10 µg/kg range via intraperitoneal administration in animal studies. In vitro research has demonstrated activity at nanomolar concentrations. These are the empirical reference points available from the published literature.

The distinction matters because BPC-157 is fundamentally different in its evidence stage from compounds like semaglutide or tirzepatide, where human pharmacokinetics are well-characterised through large-scale clinical trial programmes. BPC-157 is a research chemical — genuinely interesting, mechanistically active in preclinical models, and still at the stage of building the preclinical evidence base required to justify formal human investigation. Pure Grade Labs supplies BPC-157 10mg for that preclinical research purpose, with HPLC-verified purity and batch-specific COA documentation.

Researchers interested in tissue repair models may also find value in examining TB-500 alongside BPC-157, given the mechanistic complementarity documented in the literature. Both are available from Pure Grade Labs individually or as a research combination in the Wolverine Recovery Research Stack and the Injury Recovery Research Stack. All products are supplied strictly for laboratory research purposes only.

References

  1. Sikiric P, Hahm KB, Bhattacharya S, et al. (2018). Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and gastrointestinal tract healing, cell survival and cell migration are the Key Mechanisms. Current Pharmaceutical Design, 24(18), 1990–2001.
  2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780.
  3. DeFoor MT, Moorman CT, Petri M. (2024). The Current State of BPC-157 Research: A Systematic Review of the Literature. Arthroscopy. PMC12313605.
  4. Sikiric P, Seiwerth S, Rucman R, et al. (2013). Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design, 20(7), 1126–1135.
  5. Vukojevic J, Milavic M, Perovic D, et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research, 17(3), 482–487.
  6. Gwyer D, Bhatt DL, Bhattacharya S. (2019). BPC-157 and standard of care: the current state of BPC-157. Considerations and gaps in the literature. Expert Opinion on Investigational Drugs. Review.
Disclaimer: All Pure Grade Labs products are sold as research chemicals for laboratory research purposes only. Not for human consumption. This article does not constitute medical or prescribing advice. The information presented is drawn from published preclinical research literature and is provided for educational and research reference purposes. Consult a qualified medical professional for any health or treatment-related questions.